Compare Danaher Corporation (DHR) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Texas Instruments Incorporated — how do they compare? Danaher Corporation trades at $205.43 (market cap $144.67B), while Texas Instruments Incorporated trades at $278.59 (market cap $252.60B). The key difference: Texas Instruments Incorporated is the larger of the two by market cap, and Texas Instruments Incorporated pays the higher dividend (2.05%). Which is the better fit depends on your goals.
| DHR | TXN | |
|---|---|---|
Market Cap | $144.67B | $252.60B |
Sector | Health | Technology |
52-Week High | $242.05 | $332.35 |
52-Week Low | $161.91 | $153.33 |
Enterprise Value | $166.88B | $259.65B |
Dividend Yield | 0.78% | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $207.44, down 0.87% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company demonstrates solid fundamentals with consistent earnings beats in recent quarters and a healthy 15.95% net income margin. Recent developments include the Masimo acquisition approval and new product launches in the SCIEX division, supporting growth prospects in biotechnology and life sciences segments.
DHR presents a mixed outlook with strong analyst support (69% buy ratings) but faces valuation concerns at a P/E of 36.98. Key opportunities include biotechnology segment growth and strategic acquisitions, while risks involve elevated valuation, competitive pressures, and potential market volatility. The stock trades above the consensus price target of $202.33, suggesting limited near-term upside despite positive fundamentals.
Texas Instruments (TXN) trades at $281.24, up 0.29% on the day, with a neutral technical signal. The company reported mixed quarterly earnings, missing in Q4 2025 but beating in Q1 and Q2 2026. Revenue for 2025 was $17.68 billion with a net income margin of 31.11%. Analyst consensus is a Buy with a $334.75 price target. Recent news highlights a CFO transition and strong AI-driven demand in data centers.
The outlook for TXN is positive, driven by AI infrastructure demand and operational leverage, but risks include high valuation multiples and increasing debt levels. Upside potential exists if the company meets Q3 2026 earnings expectations and capitalizes on analog chip growth in power management for AI and EVs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
